Omega-3 Fatty Acids Significantly Reduced Pain in Obese Patients with Breast Cancer

TON - November 2018, Vol 11, No 5 - Breast Cancer
Meg Barbor, MPH

Omega-3 fatty acids significantly reduced aromatase inhibitor (AI)-induced joint pain in obese women with breast cancer, according to a new retrospective analysis of the SWOG S0927 study, a 24-week, randomized, controlled clinical trial that compared omega-3 fatty acids and placebo in patients with AI-related arthralgia. This side effect is more often seen in obese patients with cancer who are taking AIs than in nonobese patients.

These findings were presented at the 2018 Best of ASCO meeting in Chicago by Thomas W. LeBlanc, MD, MHS, FAAHPM, Associate Professor of Medicine, Duke Cancer Institute, Durham, NC.

Although AIs do prolong survival in postmenopausal women with breast cancer, approximately 50% of patients who are taking these drugs experience arthralgia, and many discontinue their use of AIs because of severe pain. There is currently no optimal treatment regimen for this adverse effect, and previous examination of omega-3 fatty acid treatment for AI-induced arthralgia has produced mixed results.

Although the researchers found no benefit to using omega-3 fatty acids in the entire population of women with stage I-III estrogen receptor–positive or progesterone receptor–positive breast cancer in the initial SWOG S0927 randomized study, there is evidence that omega-3 fatty acids are anti-inflammatory and have been shown to reduce systemic inflammation. The researchers also wondered if omega-3 fatty acids could have an impact on AI-induced pain based on the patient’s weight. Therefore, they performed this exploratory post-hoc analysis. They used standard body mass index (BMI) to identify obese patients.

“In overweight patients there may be more stress on the bones, cartilage breakdown due to wear and tear of excessive weight, maybe more stiffness, and likely higher AI drug concentrations,” said Dr LeBlanc. “We know that omega-3 fatty acids are anti-inflammatory and are associated with reduced systemic inflammation, so some folks have wondered if that might also play out on the inflammatory component of AI-related arthralgia. That’s basically the rationale behind doing this secondary analysis,” he noted.

Post-Hoc Analysis Reveals Significant Benefit

The study enrolled 249 female patients with a Brief Pain Inventory worst pain score of 5 or more on a scale of 0 to 10. All participants had been receiving an AI for at least 90 days, and reported pain associated with their use of the drug.

The Brief Pain Inventory scale looks at the intensity and the duration of pain, the overall pain severity, and, in addition, it looks at the impact on a person’s function and their overall well-being, Dr LeBlanc said. “So it’s not just a pain score. It’s a little bit more than that,” he noted.

Participants were divided into 2 groups according to their weight—­­­139 (56%) women had a BMI of <30 kg/m2 and 110 (44%) had a BMI of ≥30 kg/m2.

Among the heavier women—patients with a BMI of ≥30 kg/m2—daily omega-3 fatty acid use significantly reduced arthralgia pain compared with placebo.

Omega-3 use was associated with a 2.89-point decrease in worst pain scores at 24 weeks (the study’s primary end point) compared with only a 1.49-point decrease with placebo use. This group also saw significantly reduced triglyceride levels at 12 weeks compared with placebo.

However, among women with a BMI of <30 kg/m2, the pain scores and triglyceride levels did not significantly differ between the omega-3 fatty acid and placebo groups.

"Practice-Changing Results"

“For each of the following areas—worst pain, average pain, and pain interference—there was a significant improvement in the obese patients compared to placebo,” suggested Dr LeBlanc. “You don’t see that in the nonobese patients. So ultimately, this post-hoc analysis showed us a relevant subgroup where a patient with AI-related arthralgia might be more likely to respond to, and perhaps meaningfully benefit from, omega-3 fatty acid supplementation,” he added.

If the study results are confirmed, omega-3 fatty acid use may lead to improved adherence to AIs in this subset of obese patients with breast cancer, according to the investigators.

“This is an effective, well-tolerated, inexpensive and widely available treatment option for the management of a hard-to-treat symptom in individuals who are obese on AI therapy,” Dr Le­Blanc continued.

“So this is a potentially practice-­changing insight from the Patient and Survivor Care track of this year’s ASCO annual meeting,” he added.

This study was originally presented at ASCO 2018 by Sherry Shen, MD, Resident, Columbia University Medical Center, New York City.

Related Items
Managing Bone Metastases Through a Multidisciplinary Approach
Meg Barbor, MPH
JHOP Web Exclusives published on December 11, 2018 in Supportive Care
Helping Patients, Caregivers, and Survivors Navigate Cancer Support Resources: The Art of Connecting People
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Survivorship
High Rates of Sleep Deficiency and Cancer-Related Fatigue Across Diagnoses
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Symptom Management Overview
Cannabis for Symptom Management in Cancer: Do You Know What Your Patients Are Using?
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Symptom Management Overview
Oral Toxicities Associated with Cancer Therapies: What's Old Is New Again
Meg Barbor, MPH
JHOP Web Exclusives published on November 26, 2018 in Drug Therapies
The Pharmacist’s Role in Improving Quality in Oncology
Meg Barbor, MPH
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA 2018 Highlights
Know Your Target: Precision Medicine 101
Meg Barbor, MPH
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in ONS 2018
The Samfund Provides Financial Support for Young Adult Cancer Survivors
Meg Barbor, MPH
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Survivorship
Adherence to Exercise and Nutrition Guidelines Can Prolong Life in Cancer Survivors
Meg Barbor, MPH
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Survivorship
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Last modified: December 4, 2018